Exponential Learning
Thermo Fisher Q3 2026: The Lab Recovery Is Real
17:21
Thermo Fisher beat and raised: revenue +9% to $12.14B with 6% organic growth, adjusted EPS +15% to $6.68, and FY26 guidance lifted on revenue, EPS and free cash flow. Pharma Services and clinical research led, China grew low double digits, and biotech funding is improving — the life-sciences spending recovery is real. The honest footnotes: about $0.15 of the EPS beat was a one-time tariff…